Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

PGC-1α research offers new hope for weight loss by boosting metabolic efficiency and providing accessible management ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

Counterfeit versions of Wegovy or Zepbound are different from compounded weight loss drugs. Compounding is a legitimate practice that’s monitored by the Food and Drug Administration. Compounded ...

GLP-1 drugs mimic a hormone in the intestinal tract to balance the body’s blood sugar levels. And while GLP-1 drugs such as ...

Research backs this up: Young men who consumed more protein while losing weight and on an intense exercise regiment gained ...

New FDA draft guidance for drugmakers focuses on trial design for developing obesity treatments. Read more here.

With 13 states offering coverage, it’s already a $3.9 billion cost. Some state officials say reducing obesity will save programs money in the long run.

A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, manufactured by Novo Nordisk. Reuters Eli Lilly said Wednesday that its obesity drug Zepbound ...

Losing weight by dieting (restricting energy) includes, along with fat loss, losing lean mass, about half of which is ...